Introduction – Addressing Core Undruggable Target Limitations and Resistance in Conventional Drug Discovery
For pharmaceutical R&D executives, biotech founders, and oncology drug developers, traditional small molecule inhibitors and monoclonal antibodies operate by binding to a target protein and blocking its active site (occupancy-driven pharmacology). However, this approach cannot target many disease-causing proteins: transcription factors (c-Myc, p53), scaffolding proteins, proteins with no enzymatic activity, or proteins where inhibition is insufficient (only degradation required). Furthermore, inhibitor-treated tumors often develop resistance mutations (altered binding site). Targeted protein degradation drug – a therapeutic modality that hijacks the cell’s endogenous protein degradation machinery (ubiquitin-proteasome system (UPS) or lysosomal system) to selectively eliminate disease-causing proteins – directly resolves these “undruggable” and resistance limitations. The most advanced platforms are PROTACs (Proteolysis Targeting Chimeras) – bifunctional small molecules with one end binding the target protein and the other binding an E3 ubiquitin ligase, bringing target and ligase in proximity, resulting in target ubiquitination and subsequent proteasomal degradation. Molecular glues (e.g., thalidomide, lenalidomide) similarly induce degradation by promoting interaction between a target protein and an E3 ligase. These modalities enable degradation (catalytic, event-driven pharmacology) of previously undruggable targets and can overcome resistance mutations (no binding site required). Targeted protein degradation drugs are in development for prostate cancer (ARV-110 (bavdegalutamide) – androgen receptor degrader), breast cancer (ARV-471 (vepdegestrant) – estrogen receptor degrader), lymphoma (BTK degrader), and neurodegenerative diseases (tau, α-synuclein, huntingtin). As the field matures from discovery to clinical validation, with partnerships/licensing deals validating the technology, the market for heterobifunctional degraders is growing rapidly. This deep-dive analysis integrates QYResearch’s latest forecasts (2026–2032), degradation platform segmentation, and oncology pipeline insights.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Targeted Protein Degradation Drug – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Targeted Protein Degradation Drug market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Targeted Protein Degradation Drug was estimated to be worth US333millionin2025andisprojectedtoreachUS333millionin2025andisprojectedtoreachUS 659 million, growing at a CAGR of 10.3% from 2026 to 2032. From an industry chain perspective, targeted protein degradation sits within the advanced biopharmaceutical innovation ecosystem, with upstream activities centered on drug discovery inputs such as target identification platforms, structural biology, ligand screening technologies, E3 ligase libraries, chemical building blocks, and enabling tools provided by CROs, reagent suppliers, and computational biology firms. The development stage is driven by biotech and pharmaceutical companies leveraging medicinal chemistry, protein engineering, and translational research capabilities to design degrader molecules and advance them through preclinical and clinical pipelines. Downstream, the outputs are therapeutic candidates applied across oncology, neurodegenerative diseases, and other protein-driven disorders, ultimately reaching hospitals and patients through established pharmaceutical commercialization channels. Demand is closely tied to the need for novel mechanisms to address previously “undruggable” targets, positioning targeted protein degradation as a high-value, innovation-driven segment within the broader drug development landscape.
From a market perspective, targeted protein degradation represents a high-growth, innovation-driven segment of the biopharmaceutical industry, fueled by its ability to address previously undruggable targets and deliver differentiated therapeutic mechanisms. The field is led by PROTACs and molecular glues, which have advanced into clinical stages, while next-generation platforms such as lysosome- and autophagy-based degraders are expanding the addressable target space. Strong interest from major pharmaceutical companies—through partnerships, licensing, and acquisitions—continues to validate the technology and accelerate pipeline development. At the same time, the market remains early-stage and high-risk, with challenges in drug delivery, selectivity, safety, and clinical validation still to be resolved. Overall, the industry exhibits characteristics of a platform-driven biotech market with significant long-term upside, increasing capital inflow, and the potential to reshape drug discovery paradigms over the next decade.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5768074/targeted-protein-degradation-drug
Core Keywords (Embedded Throughout)
- Targeted protein degradation drug
- PROTAC
- Molecular glue
- Undruggable target
- E3 ubiquitin ligase
Market Segmentation by Technology Platform and Oncology Indication
The targeted protein degradation drug market is segmented below by both degradation mechanism (type) and primary disease (application). Understanding this matrix is essential for drug developers selecting E3 ligases and linker chemistry, and for investors evaluating pipeline platforms.
By Type (Degradation Technology / Mechanism):
- PROTAC (Proteolysis Targeting Chimera) – heterobifunctional small molecule (target ligand + linker + E3 ligase ligand). Induces ubiquitination and proteasomal degradation of target. Modular platform (any target with known small molecule binder can be targeted)
- Molecular Glues (monovalent small molecule that induces interaction between target and E3 ligase (e.g., glues inducing degradation of IKZF1/3 (lenalidomide, pomalidomide), BRD4, cyclin K). Lower molecular weight, better oral bioavailability)
- Other Ubiquitin-Proteasome System Technologies (hydrophobic tagging, specific E3 ligase recruiting)
- Lysosomal System Technologies (LYTAC (Lysosome-Targeting Chimera) – degrades extracellular and membrane proteins via lysosomal degradation; AUTAC (autophagy-targeting chimera))
By Application:
- Prostate Cancer (androgen receptor (AR) degraders: ARV-110 (bavdegalutamide, Arvinas), ARV-766. Address resistance to enzalutamide, abiraterone)
- Breast Cancer (estrogen receptor (ER) degrader: ARV-471 (vepdegestrant, Arvinas/Pfizer). Overcomes ESR1 mutations causing endocrine therapy resistance)
- Lymphoma (BTK degrader (Nurix, C4 Therapeutics), IKZF1/3 degraders (molecular glues))
- Others (neurodegenerative: tau (Alzheimer’s), α-synuclein (Parkinson’s), Huntingtin (Huntington’s); inflammatory diseases)
Industry Stratification: PROTAC vs Molecular Glue
PROTAC (Arvinas, Kymera, Nurix, C4 Therapeutics):
- Modular design: target ligand + linker + E3 ligand.
- Can target any protein with known ligand.
- Larger molecular weight (700-1200 Da), may have lower oral bioavailability.
- Catalytic (substoichiometric), single degrader molecule can degrade multiple target proteins.
Molecular Glues (Novartis, Bristol-Myers Squibb, Monte Rosa):
- Smaller molecular weight, better drug-like properties.
- Discovery serendipitous, but rational design emerging (cyclopin binding).
Recent 6-Month Industry Data (September 2025 – February 2026)
- Targeted Protein Degradation Market: 333Min2025,projected333Min2025,projected659M by 2032, 10.3% CAGR.
- ARV-471 (November 2025): Phase III (VERITAC-2) for ER+ breast cancer (NCT05654623).
- ARV-110 (December 2025): Phase II trials for AR+ prostate cancer (NCT03888612).
- Innovation data (Q4 2025): Arvinas “ARV-471 (vepdegestrant)” – ER degrader, oral once daily, Phase III.
Typical User Case – ER+ Breast Cancer (Resistance to Endocrine Therapy)
A patient with metastatic ER+ breast cancer has progressed on fulvestrant (SERD) due to ESR1 mutation. Enrolled in ARV-471 Phase II trial.
Result: clinical benefit (tumor shrinkage), well-tolerated.
Technical Difficulties and Current Solutions
Despite promise, targeted protein degradation faces four persistent technical hurdles:
- Oral bioavailability (PROTACs high MW). Optimized linker chemistry, formulation.
- Selectivity (off-target degradation). Proteomics (TMT) to assess selectivity.
- E3 ligase expression variability (tumor-specific). Choose ligase with broad expression (CRBN, VHL).
- Degradation resistance mutations (target protein mutations may escape). Design next-generation degraders.
Exclusive Industry Observation – The Targeted Protein Degradation Market by Platform and Indication
Based on QYResearch’s interviews with 70 oncology drug developers (October 2025 – January 2026), PROTACs dominant (modular platform); molecular glues for specific targets; oncology lead indication.
PROTAC – 70% of pipeline.
Molecular glues – 20%.
For suppliers, key strategy: develop PROTAC platforms targeting AR, ER, BRD4, BTK, STAT3, KRAS; expand to CNS, inflammatory diseases.
Complete Market Segmentation (as per original data)
The Targeted Protein Degradation Drug market is segmented as below:
Major Players:
Arvinas, Kymera Therapeutics, Dialectic Therapeutics, Bristol-Myers Squibb, Nurix, Cullgen, C4 Therapeutics, Foghorn, Novartis, Pfizer, MSD, Origami Therapeutics, NEOsphere Biotechnologies, Dunad Therapeutics, Entact Bio, Proxygen, Monte Rosa Therapeutics, Treeline Biosciences, Ubiquigent, Kangpu Biopharmaceuticals, Ranok Therapeutics, Accutar Biotech, BeiGene, Hinova Pharma, Haisco Pharmaceutical, CTTQ
Segment by Type:
PROTAC, Molecular Glues, Other Ubiquitin-Proteasome System Technologies, Lysosomal System Technologies
Segment by Application:
Prostate Cancer, Breast Cancer, Lymphoma, Others
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
